Mizuho Downgrades Terns Pharmaceuticals (TERN) to Neutral on Merck acquisition

March 27, 2026 8:50 AM

Mizuho analyst Graig Suvannavejh downgraded Terns Pharmaceuticals (NASDAQ: TERN) from Outperform to Neutral with a price target of $53.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found